University of Minnesota’s World-Renowned Fanconi Anemia Treatment and Research Program Renamed

July 11, 2018
Published by
Published by: 
Krystle Barbour, Media and Public Relations Specialist

University of Minnesota Masonic Children's Hospital is the largest treatment center in the United States for patients with the rare genetic disease Fanconi anemia (FA). In recognition of Kidz1stFund, which has donated more than $5.5 million for FA research at Masonic Children’s, the University of Minnesota’s treatment and research program for FA will become the Kidz1stFund Comprehensive Fanconi Anemia Center.

Jimbo Fisher and Candi Fisher founded Kidz1stFund in 2011, when their youngest son was diagnosed with Fanconi anemia, a rare, genetic disease that leads to bone marrow failure and other conditions. It affects about one in every 131,000 births each year.

Read the news release for more information about how Kidz1stFund and the U of M are working together to improve the success of blood and marrow transplants for people with FA.

Share this post

You may also like:

GT MedTech’s innovative GammaTile Therapy is shown to slow brain tumor progression, designed to improve patient and caregiver quality of life.

Perlingeiro’s lab, over several years, pioneered the development of muscle stem/progenitor cells from pluripotent stem cells in vitro.

Researchers create the first 3D in vitro model capable of isolating specific metastatic cells.